In our previous studies, we demonstrated the antifibrotic activity of HE in hepatic stellate cells (LX-2) activated by TGF-β or activated with a mixture of NAFLD-promoting agents (NPAs) to mimic the pathophysiological environment observed in NAFLD/NASH patients. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.